Compare ProShares Ultra Silver ETF (AGQ) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Amgen, Inc. — how do they compare? ProShares Ultra Silver ETF trades at $80.29, while Amgen, Inc. trades at $416.99 (market cap $224.14B). The key difference: Amgen, Inc. pays a 2.43% dividend while ProShares Ultra Silver ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | AMGN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $417.20 |
52-Week Low | $49.73 | $271.18 |
Market Cap | — | $224.14B |
Enterprise Value | — | $267.45B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGQ, the ProShares Ultra Silver ETF, trades at $81.00, down 1.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The leveraged ETF structure amplifies silver price moves, with recent volatility highlighted by a 9.39% surge on silver rallies but a 16% crash in June 2026. Financial ratios are not applicable as this is an ETF tracking silver futures.
Outlook hinges on silver price direction, offering amplified gains if silver rallies but severe decay in downturns. Key risks include structural decay from daily leverage resets and silver's sensitivity to Fed policy. Investors must weigh high volatility against silver's bullish momentum.
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
